Clinical trial · Interventional
A Study: Pure CBD as Single-agent for Solid Tumor.
NCT02255292CI-TRIAL-00015765unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Increasing lines of evidence support an antitumourigenic effect of cannabinoids, including the cannabidiol (CBD) which does not posses the psychotropic effects of D9-tetrahydrocannabinol (THC). These include anti-proliferative and pro-apoptotic effects and they are known to interfere with several mechanisms in the tumorgenesis. Yet, evidence from clinical trials among cancer patients is needed. The aim of the current study is to evaluate the impact of CBD as single treatment among cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cannabidiol (CBD) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- cannabidiol (CBD)
- description
- Patients with confirmed solid cancer, after progression of all the available standard therapy or unfit to standard therapy according to oncologist's view, measurable disease as determined by RECIST using CT, life expectancy of at least 6 months, Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2 and aged 18 years old and more will be included in the current study.
- interventionNames
- Drug: cannabidiol (CBD)
Primary outcomes (1)
- measure
- Overall Response Rate according to RECIST 1.1
- timeFrame
- At baseline and at 8 weeks from time of first dose, by CT scans for RECIST 1.1
- description
- ORR per RECIST 1.1 calculated as the proportion of patients with a best overall response defined as complete response or partial response (CR+PR) as assessed by investigatorand RECIST criteria.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed solid cancer * Approved license for using cannabis (from the ministry of health: Israel) * Progression of all the available standard therapy / unfit to standard therapy according to oncologist's view * Measurable disease as determined by RECIST * Life expectancy of at least 6 months * Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2 * Aged 18 years old and more Exclusion Criteria: * Received cannabis therapy for any indication * Previous systemic therapy of less than 3 weeks prior to and, if present, any acute toxicity \> grade 1. * Clinically significant cardiac disease or any history of psychosis * Pregnancy or breast feeding
References
Publications (1)
- BACKGROUNDMechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol--recent advances. Chem Biodivers. 2007 Aug;4(8):1678-92. doi: 10.1002/cbdv.200790147. PMID 17712814